Physician profile
Mark O Herring
NPI 1689636284
$1,184.18
in general payments reported to CMS, 2019-2025
28 companies · $183 in 2025
The $183 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $81.07 · 2021: $188 · 2022: $190 · 2023: $143 · 2024: $196 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $522.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $289.09 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $148.26 | 2019-2025 | |
| Biogen, INC. | $101.96 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $77.00 | 2021 | |
| Neurocrine Biosciences, INC. | $43.33 | 2020-2022 | |
| Lundbeck LLC | $39.27 | 2024-2025 | Vyepti |
| Sunovion Pharmaceuticals INC. | $37.57 | 2020-2021 | |
| Advanced Respiratory, INC | $35.88 | 2019 | |
| Allergan, INC. | $33.99 | 2020-2021 | |
| Emd Serono, INC. | $33.10 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $32.60 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $30.06 | 2019 | |
| Nalu Medical, INC. | $24.51 | 2023 | Nalu Neurostimulation System |
| Greenwich Biosciences, INC. | $21.99 | 2021 | |
| Sumitomo Pharma America, INC. | $20.53 | 2023 | Aptiom |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $20.20 | 2021 | |
| Pfizer INC. | $19.77 | 2025 | |
| Sarepta Therapeutics, INC. | $19.56 | 2019 | |
| Immedica Pharma US, INC. | $18.63 | 2023 | |
| Impel Pharmaceuticals INC. | $17.70 | 2022 | |
| Ucb, INC. | $16.87 | 2020 | |
| Avion Pharmaceuticals | $16.40 | 2022 | |
| Supernus Pharmaceuticals, INC. | $15.95 | 2019 | |
| Boston Scientific Corporation | $15.68 | 2021 | |
| Adamas Pharmaceuticals, INC. | $15.59 | 2019 | |
| Acadia Pharmaceuticals INC | $13.29 | 2019 | |
| Alnylam Pharmaceuticals INC. | $13.01 | 2023 | Amvuttra |
| Genentech USA, INC. | $12.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Herring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.